Reducing Barriers to Symptom Management and Palliative Care
The summary for the Reducing Barriers to Symptom Management and Palliative Care grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Reducing Barriers to Symptom Management and Palliative Care: The purpose of this RFA is to solicit grant applications for research directed at developing and testing interventions to reduce or overcome barriers to the delivery of appropriate symptom management and palliative care to patients suffering from disease and/or treatment- related sequelae. Historically, the cancer symptom management research community has focused largely on describing symptom prevalence and testing new interventions to ameliorate one or more symptoms. Many of these studies have shown efficacy, yet, because of a number of patient, clinician, and health system-related barriers, the larger cancer community is not adopting these findings. Research is needed to discover new or innovative way to implement evidenced based practices into routine clinical care. We must expand and accelerate our potential to address the problems of inadequate symptom management and palliative care among diverse populations in the United States. Given NCIs challenge goal of eliminating the suffering and death due to cancer by 2015, efforts must be directed to improving the delivery of treatments to prevent or ameliorate the adverse physical and psychosocial consequences associated with the diagnosis and treatment of cancer.
|Federal Grant Title:||Reducing Barriers to Symptom Management and Palliative Care|
|Federal Agency Name:||National Institutes of Health|
|Grant Categories:||Health Education|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||RFA-CA-05-013|
|Type of Funding:||Grant|
|CFDA Descriptions:||Nursing Research 93.399 Cancer Control|
|Current Application Deadline:||No deadline provided|
|Original Application Deadline:||Sep 24, 2004|
|Posted Date:||Jun 01, 2004|
|Creation Date:||Jun 01, 2004|
|Archive Date:||Oct 24, 2004|
|Total Program Funding:|
|Maximum Federal Grant Award:|
|Minimum Federal Grant Award:|
|Expected Number of Awards:|
|Cost Sharing or Matching:||No|
- Applicants Eligible for this Grant
- State governments County governments City or township governments Special district governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Small businesses
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster FBOWebmaster@OD.NIH.GOV NIH OER Webmaster
- More Grants from the National Institutes of Health
- • Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource...
- • Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24)...
- • New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not...
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Tria...